Lazard Capital Upgrades Orexigen Therapeutics (OREX) to Neutral
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Join SI Premium – FREE
Lazard Capital upgraded Orexigen Therapeutics (NASDAQ: OREX) from Sell to Neutral.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $1.51 yesterday.
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $1.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- Investec Double Upgrades Alkem Laboratories Ltd (ALKEM:IN) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
